A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
NCT05768269
Recruiting
This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluation of any late adverse events (AEs) that may appear after treatment with such cellular products. Additionally, collection of persistence data from participants will support the identification of any lo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +6 locations
Conditions: Hematological Malignancy, Solid Tumor Malignancy
Register for Updates
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
NCT05780879
Recruiting
The primary purpose of this study is to determine complete remission rate of a novel combination induction chemotherapy treatment based upon 20 patients with newly diagnosed secondary AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Secondary Acute Myeloid Leukemia
Register for Updates
OCT in Open Fracture and Infected Fracture
NCT05785182
Recruiting
This is a pilot prospective, observational study of patients with open or infected fracture evaluating the feasibility and acceptability of OCT, a light-based imaging modality that requires no drug or contrast agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Trauma Injury, Trauma, Open Fracture, Fracture Infection
Register for Updates
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807
Recruiting
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +742 locations
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
SMARTer Weight Loss Management
NCT05861973
Recruiting
The SMARTer trial will be a three-arm, randomized controlled non-inferiority trial that compares the optimized, adaptive SMARTer intervention, fixed DPP, and Self-Guided (Control). The trial will address whether a scalable, stepped-care intervention can stand up to gold-standard DPP by achieving comparable weight loss at a lower cost. Alongside evaluation of clinical non-inferiority, a comprehensive economic evaluation will inform relative affordability. Cost information is important to inform t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Obesity
Register for Updates
Precision Medicine Approaches to Renal Osteodystrophy
NCT05880914
Recruiting
Treatment of renal osteodystrophy is impeded by the lack of practical and accurate tools to determine underlying bone turnover. Gold standard bone biopsy is not practical in the clinic for the vast majority of kidney disease patients and parathyroid hormone and bone alkaline phosphatase have insufficient accuracy for turnover type to safely and confidently guide treatment of renal osteodystrophy. In the present investigation, the investigators will study a microRNA approach as a novel non-invasi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Washington University in St. Louis (WashU), Saint Louis, Missouri
Conditions: Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder, Secondary Hyperparathyroidism
Register for Updates
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
NCT05896163
Recruiting
The purpose of this study is to learn about the effects of two study medicines (maplirpacept \[PF-07901801\] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed means has returned after last treatment. Refractory means that it has not responded to last treatment. The two study medicines are given after a single dose of obinutuzumab which is the third study medicine. DLBCL is a type of non-Hodgkin lymphoma (NH... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: The University of Kansas Cancer Center ,Investigational Drug Services, Fairway, Kansas +26 locations
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates
Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain
NCT05909709
Recruiting
The purpose of this study is to see if the use of Alocyte (cord blood plasma plus mononucleic cells) will be safe, well tolerated, and whether it causes any side effects. The study will also examine if the use of the Investigational Product (IP) is able to reduce local inflammation or alleviate Facetogenic back pain
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: The Center for Regenerative Medicine, North Miami, Florida
Conditions: Facet Joints; Degeneration, Back Pain, Facet Joint Pain
Register for Updates
Examining the Role of Female Endogenous Sex Hormones in Eccentric Exercise
NCT05934708
Recruiting
The fluctuating concentrations of female sex hormones, namely estrogen and progesterone may have an effect on the ability of the tissue to withstand challenging exercise conditions, such as eccentric exercise. These sex hormones have also been purported to influence the perceived difficulty of exercise. This study aims to uncover how the different estrogen and progesterone concentrations present throughout the menstrual cycle effect perceived readiness to perform, perceptions of difficulty, and... Read More
Gender:
FEMALE
Ages:
Between 18 years and 35 years
Trial Updated:
06/24/2025
Locations: Clinical Exercise Research Center, Los Angeles, California
Conditions: Inflammatory Response
Register for Updates
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT05976763
Recruiting
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/24/2025
Locations: Tower Cancer Research Foundation, Beverly Hills, California +212 locations
Conditions: Mantle Cell Lymphoma
Register for Updates
TmCD19-IL18 in CD19+ Cancers
NCT05989204
Recruiting
This is a Phase I, open-label dose finding study to assess the safety and feasibility, pharmacokinetics, and preliminary efficacy of TmCD19-IL18 CAR T cells in patients with CD19+ cancers. This study will take place in two parts: a Dose-Finding Phase to determine the maximum tolerate dose (MTD), followed by a Dose Expansion Phase. In the Dose-Finding Phase, dose levels will be evaluated using a 3+3 dose escalation design to determine the MTD. Cumulative safety experience and manufacturing feasib... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Non Hodgkin Lymphoma
Register for Updates
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493
Recruiting
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Research Site, Jacksonville, Florida +24 locations
Conditions: Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
Register for Updates